| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author Index
|
|
|
2007
|
16 |
S1 |
p. S67-S71
5 p.
|
artikel
|
| 2 |
Editorial board
|
|
|
2007
|
16 |
S1 |
p. i-
1 p.
|
artikel
|
| 3 |
P92 Accelerated partial breast irradiation (APBI) using interstitial high dose rate brachytherapy (HDR BT): early toxicity and technical aspects
|
Kute, A.
|
|
2007
|
16 |
S1 |
p. S38-S39
2 p.
|
artikel
|
| 4 |
P70 Accuracy of sentinel lymph node biopsy in breast cancer patients treated by neoadjuvant chemotherapy
|
Park, K.M.
|
|
2007
|
16 |
S1 |
p. S32-
1 p.
|
artikel
|
| 5 |
P33 A comparative study on the value of FDG-PET & SNB to identify axillary metastases
|
Santos Silva, L.
|
|
2007
|
16 |
S1 |
p. S21-
1 p.
|
artikel
|
| 6 |
P180 A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)
|
Rapoport, B.L.
|
|
2007
|
16 |
S1 |
p. S64-
1 p.
|
artikel
|
| 7 |
P111 Adherence to tamoxifen therapy
|
Barron, T.I.
|
|
2007
|
16 |
S1 |
p. S44-
1 p.
|
artikel
|
| 8 |
P120 Adjuvant therapies: distant disease-free survival as a predictor of overall survival
|
Rugo, H.
|
|
2007
|
16 |
S1 |
p. S47-
1 p.
|
artikel
|
| 9 |
P125 Adriamycin–cytoxan followed by weekly taxol as neoadjuvant treatment in localised breast cancer
|
Leviov, M.
|
|
2007
|
16 |
S1 |
p. S48-S49
2 p.
|
artikel
|
| 10 |
P56 Age dependent variability in interaction of hormone receptors and HER2 neu and its prognostic implication in early breast cancer: A retrospective analysis in South Indian women
|
Attili, V.S.S.
|
|
2007
|
16 |
S1 |
p. S28-
1 p.
|
artikel
|
| 11 |
P39 Age-group specific mammography coverage in the Hungarian nation-wide organized breast cancer screening programme
|
Boncz, I.
|
|
2007
|
16 |
S1 |
p. S23-
1 p.
|
artikel
|
| 12 |
P34 Alternative method for the diagnosis of early breast cancer using plasma free amino acid profiles
|
Okamoto, N.
|
|
2007
|
16 |
S1 |
p. S22-
1 p.
|
artikel
|
| 13 |
P118 ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 2-06/N063D/EGF106708]: a phase III study for HER2-overexpressing early breast cancer (BC)
|
Piccart-Gebhart, M.J.
|
|
2007
|
16 |
S1 |
p. S46-S47
2 p.
|
artikel
|
| 14 |
P101 A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer
|
De Tursi, M.
|
|
2007
|
16 |
S1 |
p. S41-
1 p.
|
artikel
|
| 15 |
P100 A multicenter study of docetaxel/cyclophosphamide combination as adjuvant therapy for node negative breast cancer – JECBC04 STUDY
|
Tabei, T.
|
|
2007
|
16 |
S1 |
p. S41-
1 p.
|
artikel
|
| 16 |
P122 A multicenter study of epirubicin-docetaxel (ET) as primary chemotherapy for patients with inflammatory breast cancer (IBC)
|
Anan, K.
|
|
2007
|
16 |
S1 |
p. S48-
1 p.
|
artikel
|
| 17 |
P35 Analyses of serum samples from breast cancer patients using a novel biomarker assay
|
Ni Bhrian, P.
|
|
2007
|
16 |
S1 |
p. S22-
1 p.
|
artikel
|
| 18 |
P177 An analysis of non-drug costs associated with administration of intravenous therapies in early stage breast cancer patients
|
Kruse, G.
|
|
2007
|
16 |
S1 |
p. S63-
1 p.
|
artikel
|
| 19 |
P155 Anastrozole and letrozole – an investigation and comparison of quality of life, tolerability and morbidity
|
Dixon, J.M.
|
|
2007
|
16 |
S1 |
p. S57-
1 p.
|
artikel
|
| 20 |
P107 Anemia during adjuvant chemotherapy for early breast cancer: incidence and risk factors – Results from the International Breast Cancer Study Group (IBCSG)
|
Giann, L.
|
|
2007
|
16 |
S1 |
p. S43-
1 p.
|
artikel
|
| 21 |
P29 A new one-step nucleic acid amplification (OSNA) with cytokeratin (CK)19 mRNA for intra-operative detection of lymph node (LN) metastasis in breast cancer patients: results from the Multi-institutional Clinical Study
|
Masuda, N.
|
|
2007
|
16 |
S1 |
p. S20-
1 p.
|
artikel
|
| 22 |
P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)
|
Brufsky, A.
|
|
2007
|
16 |
S1 |
p. S57-
1 p.
|
artikel
|
| 23 |
P83 A novel method of CT-scan based localization of the internal mammary chain by internal mammary catheterization: an aid in breast cancer radiation therapy planning
|
Munsh, A.
|
|
2007
|
16 |
S1 |
p. S36-
1 p.
|
artikel
|
| 24 |
P64 A randomized trial of axillary dissection versus no axillary dissection for patients with clinically node negative breast cancer and micrometastases in the sentinel node
|
Galimberti, V.
|
|
2007
|
16 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 25 |
P36 Assessment of bone metastases using bone scan and PET/CT imaging in patients with breast cancer
|
Lee, Y.H.
|
|
2007
|
16 |
S1 |
p. S22-
1 p.
|
artikel
|
| 26 |
P137 Assessment of parameters of response to combined modality treatment of locally advanced breast cancer
|
Singha, N.
|
|
2007
|
16 |
S1 |
p. S52-
1 p.
|
artikel
|
| 27 |
P14 A study for cell cycle arrest and apoptosis induced by PPARr agonist in MDA-MB-231 breast cancer cells
|
Youn, H.J.
|
|
2007
|
16 |
S1 |
p. S16-
1 p.
|
artikel
|
| 28 |
P62 A study to investigate the role of p27 and cyclin E immunoexpression as a prognostic factor in early breast carcinoma
|
Pillay, K.
|
|
2007
|
16 |
S1 |
p. S30-
1 p.
|
artikel
|
| 29 |
P175 ATAC – a case study on the impact of clinical trial data presentations and agency guidelines/technology assessments on clinical practice
|
Chlebowski, R.
|
|
2007
|
16 |
S1 |
p. S63-
1 p.
|
artikel
|
| 30 |
P32 Axillary lymph node involvement in breast cancer decreases with age but increases again after age 70 mainly in small tumors
|
Wildiers, H.
|
|
2007
|
16 |
S1 |
p. S21-
1 p.
|
artikel
|
| 31 |
P66 Axillary study before surgery in patients with breast cancer
|
Izquierdo Sanz, M.
|
|
2007
|
16 |
S1 |
p. S31-
1 p.
|
artikel
|
| 32 |
P42 Before MRI what? Treatment and follow-up of patients who underwent breast conservative surgery for breast cancer without preoperative MRI evaluation
|
Vassilaro, S.
|
|
2007
|
16 |
S1 |
p. S24-
1 p.
|
artikel
|
| 33 |
P11 Biologic behavior of E-cadherin in invasive ductal carcinoma
|
Bae, J.
|
|
2007
|
16 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 34 |
P140 Bone turnover markers in postmenopausal breast cancer patients treated with fulvestrant
|
Robertson, J.F.R.
|
|
2007
|
16 |
S1 |
p. S53-
1 p.
|
artikel
|
| 35 |
P71 Breast cancer and internal mammary sentinel node (IMSN)
|
Nogaret, J.-M.
|
|
2007
|
16 |
S1 |
p. S32-
1 p.
|
artikel
|
| 36 |
P184 Breast cancer diagnosis and therapy cost analysis per disease stages in a Portuguese oncology hospital
|
Nogueira, M.F.
|
|
2007
|
16 |
S1 |
p. S65-
1 p.
|
artikel
|
| 37 |
P158 Breast cancer frequency in families with a child having acute lymphoblastic leukemia
|
Kitsera, N.
|
|
2007
|
16 |
S1 |
p. S58-
1 p.
|
artikel
|
| 38 |
P159 Breast cancer in Arab and Jewish women: differences in clinical and pathological characteristics
|
Sikorsky, N.
|
|
2007
|
16 |
S1 |
p. S58-S59
2 p.
|
artikel
|
| 39 |
P160 Breast cancer patients aged 80 years or over
|
Rabkin, A.
|
|
2007
|
16 |
S1 |
p. S59-
1 p.
|
artikel
|
| 40 |
P141 Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate
|
Costa, L.
|
|
2007
|
16 |
S1 |
p. S53-
1 p.
|
artikel
|
| 41 |
P185 Breast cancer treatment program: intermediate dose autologous transplants and a non-myeloablative reduced intensity allogeneic transplant integrated in the therapy for early breast cancer
|
Van Hoef, M.
|
|
2007
|
16 |
S1 |
p. S66-
1 p.
|
artikel
|
| 42 |
P91 Breast conservation in early disease: a comparison of intra operative and post operative HDR brachytherapy boost
|
Goswami, J.
|
|
2007
|
16 |
S1 |
p. S38-
1 p.
|
artikel
|
| 43 |
P90 Breast conserving treatment with tumorectomy and intraoperative partial breast irradiation in case of local recurrence instead of mastectomy – Presentation of a prospective-controlled trial
|
Piroth, M.D.
|
|
2007
|
16 |
S1 |
p. S38-
1 p.
|
artikel
|
| 44 |
P63 Can the histoculture drug response assay (HDRA) predict the clinical results of chemotherapy in breast cancer?
|
Jung, Y.
|
|
2007
|
16 |
S1 |
p. S30-
1 p.
|
artikel
|
| 45 |
P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer
|
Ewer, M.S.
|
|
2007
|
16 |
S1 |
p. S63-
1 p.
|
artikel
|
| 46 |
P110 Cardiac side effects in the HERceptin Adjuvant, (HERA) trial
|
Suter, T.M.
|
|
2007
|
16 |
S1 |
p. S44-
1 p.
|
artikel
|
| 47 |
P144 CELER: an international randomized phase III trial of the CESAR Group – or: Should chemotherapy be added to hormonal therapy in advanced breast cancer?
|
Sirbu, D.
|
|
2007
|
16 |
S1 |
p. S54-
1 p.
|
artikel
|
| 48 |
P109 Comparing AI cardiovascular safety data: trial comparators and outcomes
|
Monnie, A.
|
|
2007
|
16 |
S1 |
p. S43-S44
2 p.
|
artikel
|
| 49 |
P173 Comparing a novel clinico-pathological risk classification used in the node-negative-breast- cancer-3 (NNBC-3) trial with the establishedSt. Gallen Risk Classification 2005
|
Schmidt, M.
|
|
2007
|
16 |
S1 |
p. S62-
1 p.
|
artikel
|
| 50 |
P68 Comparison of early postoperative axillary morbidity between sentinel lymph node biopsy and conventional axillary lymph node dissection
|
Lee, J.S.
|
|
2007
|
16 |
S1 |
p. S32-
1 p.
|
artikel
|
| 51 |
P108 Comparison of quality of life (QOL) between adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) and oral uracil/tegafur in high-risk, node-negative breast cancer – A phase III randomized trial (N-SAS BC 01)
|
Makino, H.
|
|
2007
|
16 |
S1 |
p. S43-
1 p.
|
artikel
|
| 52 |
P179 Comparison of the cost per distant disease free year gained of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective
|
Karnon, J.
|
|
2007
|
16 |
S1 |
p. S64-
1 p.
|
artikel
|
| 53 |
P112 Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer
|
Zille, V.
|
|
2007
|
16 |
S1 |
p. S44-S45
2 p.
|
artikel
|
| 54 |
P181 Cost-effectiveness analysis of letrozole vs. tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the Belgian perspective
|
Karnon, J.
|
|
2007
|
16 |
S1 |
p. S64-S65
2 p.
|
artikel
|
| 55 |
P178 Cost-effectiveness of switching to exemestane (EX) after 2–3 years of adjuvant tamoxifen (T) in postmenopausal (PM) early breast cancer (EBC)
|
Pinto, C.G.
|
|
2007
|
16 |
S1 |
p. S64-
1 p.
|
artikel
|
| 56 |
P102 Development of a risk prediction model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy
|
Dranitsaris, G.
|
|
2007
|
16 |
S1 |
p. S41-S42
2 p.
|
artikel
|
| 57 |
P13 Differential effects of doxorubicin treatment on the expression of the ubiquitin ligase subunit Skp2 in breast cancer cells
|
Hershk, D.
|
|
2007
|
16 |
S1 |
p. S16-
1 p.
|
artikel
|
| 58 |
P127 Does neutropenia impose postponement of (neo)adjuvant chemotherapy? One year retrospective analysis in a single cancer centre
|
Deble, M.
|
|
2007
|
16 |
S1 |
p. S49-
1 p.
|
artikel
|
| 59 |
P121 Does preoperative chemotherapy influence prognosis? Evaluation of the 1998–2005 set
|
Kozevnikovova, R.
|
|
2007
|
16 |
S1 |
p. S47-
1 p.
|
artikel
|
| 60 |
P81 Effectiveness of local treatment plus tamoxifen in elderly women with early breast cancer
|
Del Prato, I.
|
|
2007
|
16 |
S1 |
p. S35-
1 p.
|
artikel
|
| 61 |
P10 Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients
|
Gjerde, J.
|
|
2007
|
16 |
S1 |
p. S15-
1 p.
|
artikel
|
| 62 |
P22 Efficacy of combination Mammotome biopsy with mammography guided needle localization for clustered microcalcifications
|
Choo, K.-S.
|
|
2007
|
16 |
S1 |
p. S18-
1 p.
|
artikel
|
| 63 |
P152 Efficacy of enoxaparin for prevention of pulmonary thromboembolism in mastectomy with immediate reconstruction in breast cancer
|
Jung, M.S.
|
|
2007
|
16 |
S1 |
p. S56-
1 p.
|
artikel
|
| 64 |
P147 Endocrine aspects of the adjuvant treatment in premenopausal breast cancer patients – getting over psycho-emotional consequences
|
Malova, J.
|
|
2007
|
16 |
S1 |
p. S55-
1 p.
|
artikel
|
| 65 |
P164 Endometrial carcinoma in breast cancer patients
|
Steiner, M.
|
|
2007
|
16 |
S1 |
p. S60-
1 p.
|
artikel
|
| 66 |
P166 Epidemiology of cancer in the mid age and elderly populations in a developing economy; need for proper resource allocation and personnel training
|
Alese, O.B.
|
|
2007
|
16 |
S1 |
p. S60-
1 p.
|
artikel
|
| 67 |
P40 Erythropoietin (EPO) and its receptors (EPOR) detection in human breast cancer specimens: correlation with steroid receptors (membrane intracellular) and other biological and clinical indices
|
Pelekanou, V.
|
|
2007
|
16 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 68 |
P4 Estrogen receptor isoforms in breast cancer: possible role in tamoxifen resistance
|
Nikolic-Vukosavljevic, D.
|
|
2007
|
16 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 69 |
P3 Evaluating the expression of HMGCS2 in human breast cancer relapses
|
Maraqa, L.
|
|
2007
|
16 |
S1 |
p. S13-
1 p.
|
artikel
|
| 70 |
P53 Evaluation of ER, and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
|
Im, Y.
|
|
2007
|
16 |
S1 |
p. S27-
1 p.
|
artikel
|
| 71 |
P129 Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer
|
Chow, W.C.L.
|
|
2007
|
16 |
S1 |
p. S50-
1 p.
|
artikel
|
| 72 |
P117 Exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): results of NSABP B-33
|
Geyer, C.E.
|
|
2007
|
16 |
S1 |
p. S46-
1 p.
|
artikel
|
| 73 |
P28 Experience of mammotome excision of benign breast disease in Korea
|
Park, H.L.
|
|
2007
|
16 |
S1 |
p. S20-
1 p.
|
artikel
|
| 74 |
P139 Experience with fulvestrant in the endocrine treatment sequence for patients with breast cancer: a Belgian compassionate use programme
|
Neven, P.
|
|
2007
|
16 |
S1 |
p. S53-
1 p.
|
artikel
|
| 75 |
P27 Expression of “basal” cytokeratins in early (pT1) ductal infiltrating carcinoma
|
Schneider, J.
|
|
2007
|
16 |
S1 |
p. S20-
1 p.
|
artikel
|
| 76 |
P105 Extracorporeal elimination of liposomal doxorubicin by therapeutic apheresis technique
|
Pütz, G.
|
|
2007
|
16 |
S1 |
p. S42-
1 p.
|
artikel
|
| 77 |
P132 Factors predicting survival after neoadjuvant therapy with aromatase inhibitors
|
Murra, E.
|
|
2007
|
16 |
S1 |
p. S50-S51
2 p.
|
artikel
|
| 78 |
P89 Feasibility, cosmetic outcome, and Quality of Life of patients receiving two different radiotherapy boost techniques for breast conservation:An Indian experience
|
Bonanthaya, R.
|
|
2007
|
16 |
S1 |
p. S37-S38
2 p.
|
artikel
|
| 79 |
P115 Fewer gynaecological adverse events (AEs), gynaecological interventions, endometrial changes and abnormalities with anastrozole than with tamoxifen: findings from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial
|
Distle, W.
|
|
2007
|
16 |
S1 |
p. S45-S46
2 p.
|
artikel
|
| 80 |
P79 Five year results of Breast Conserving Surgery for early breast cancer patients
|
Ostapenko, V.
|
|
2007
|
16 |
S1 |
p. S34-S35
2 p.
|
artikel
|
| 81 |
P85 Full-dose intraoperative radiotherapy with electrons, (ELIOT) in breast surgery: new frontiers
|
Rodriguez-Fernandez, J.
|
|
2007
|
16 |
S1 |
p. S36-
1 p.
|
artikel
|
| 82 |
P133 HER2 and topoisomerase II a: possible predictors of response to neoadjuvant chemotherapy for patients with breast cancer
|
Zh, L.
|
|
2007
|
16 |
S1 |
p. S51-
1 p.
|
artikel
|
| 83 |
P116 HER-2 expression and response to endocrine treatment in advanced breast cancer: Is there an age differential?
|
Batr, U.
|
|
2007
|
16 |
S1 |
p. S46-
1 p.
|
artikel
|
| 84 |
P57 HER-2/neu over-expression among Filipino patients with breast cancer: a 10 year review
|
Sanchez, M.T.
|
|
2007
|
16 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 85 |
P26 HER-2 overexpressed breast cancer and brain metastases
|
Lichinitse, M.
|
|
2007
|
16 |
S1 |
p. S19-
1 p.
|
artikel
|
| 86 |
P25 HER2 Testing in 538 consecutive breast cancer cases using immunohistochemistry and fluorescence in situ hybridization
|
Kovács, A.
|
|
2007
|
16 |
S1 |
p. S19-
1 p.
|
artikel
|
| 87 |
P169 Hormone therapy followed by chemotherapy are not enough for hormone receptor positive young age breast cancer: Nationwide overall survival data in Korea
|
Han, W.
|
|
2007
|
16 |
S1 |
p. S61-
1 p.
|
artikel
|
| 88 |
P48 Impact of metastatic axillary lymph node ratio on prognostic significance in stage IIIC (pN3) breast cancer
|
Lee, H.-K.
|
|
2007
|
16 |
S1 |
p. S26-
1 p.
|
artikel
|
| 89 |
P76 Improving cosmetic outcome in central breast cancer: The use of oncoplastic techniques
|
Fitzal, F.
|
|
2007
|
16 |
S1 |
p. S34-
1 p.
|
artikel
|
| 90 |
P150 Improving quality of sexual life in patients with carcinoma breast in developing countries: can we break the cultural barriers!
|
Sharma, S.
|
|
2007
|
16 |
S1 |
p. S56-
1 p.
|
artikel
|
| 91 |
P106 Incidence of chemotherapy-induced amenorrhea in pre-menopausal patients with breast cancer following adjuvant anthracycline and taxane
|
Okanami, Y.
|
|
2007
|
16 |
S1 |
p. S43-
1 p.
|
artikel
|
| 92 |
P18 Influence of the storage conditions on measurable uPA/PAI-1 protein levels in breast cancertissue specimen
|
Vetter, M.
|
|
2007
|
16 |
S1 |
p. S17-
1 p.
|
artikel
|
| 93 |
P9 Inhibition of P-glycoprotein by polyprenol in human breast cancer cells
|
Kuznecovs, S.
|
|
2007
|
16 |
S1 |
p. S15-
1 p.
|
artikel
|
| 94 |
P15 Interactions of tumorantigen-reactive T-cells derived from bone marrow and tumor-cells in breast cancer patients
|
Schuetz, F.
|
|
2007
|
16 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 95 |
P174 Inter-laboratory comparison of urokinase plasminogen activator (uPA), its inhibitor (PAI-1) and HER2 expression by means of quantitative RT-PCR in breast cancer patients
|
Vuaroqueaux, V.
|
|
2007
|
16 |
S1 |
p. S62-S63
2 p.
|
artikel
|
| 96 |
P31 Intra-operative rapid molecular diagnostic method for the detection of lymph node metastases in breast cancer
|
Meijer, C.
|
|
2007
|
16 |
S1 |
p. S21-
1 p.
|
artikel
|
| 97 |
P44 Is tumor-biological risk-assessment realistic in node-negative breast cancer? A status report of the ongoing clinical multicenter trial NNBC-3-Europe
|
Persing, M.
|
|
2007
|
16 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 98 |
P17 Letrozole (2.5 mg o.d.) is superior to anastrozole (1.0 mg o.d.) concerning suppression of both plasma and tissue estrogen levels in postmenopausal breast cancer patients
|
Geisler, J.
|
|
2007
|
16 |
S1 |
p. S17-
1 p.
|
artikel
|
| 99 |
P93 Long-term toxicity of an intraoperative radiotherapy (IORT) boost using low energy X-rays during breast conserving surgery (BCS)
|
Kraus-Tiefenbacher, U.
|
|
2007
|
16 |
S1 |
p. S39-
1 p.
|
artikel
|
| 100 |
P104 Menstrual disorders during anthracycline-based adjuvant chemotherapy in very young early breast cancer patients
|
Neskovic-Konstantinovic, Z.
|
|
2007
|
16 |
S1 |
p. S42-
1 p.
|
artikel
|
| 101 |
P12 Metallothionein as a potential molecular target in breast cancer
|
Lim, D.
|
|
2007
|
16 |
S1 |
p. S16-
1 p.
|
artikel
|
| 102 |
P73 Methylene blue and patent blue V, but not indigo carmine, stimulate DNA damage in breast cancer cells in vitro: possible implications for sentinel node biopsy practice
|
Masannat, Y.
|
|
2007
|
16 |
S1 |
p. S33-
1 p.
|
artikel
|
| 103 |
P49 Molecular characterization of E2F1 and PSMB9 expression in breast cancer and correlation with poor prognosis and disease recurrence
|
King, L.M.
|
|
2007
|
16 |
S1 |
p. S26-
1 p.
|
artikel
|
| 104 |
P88 MRC/EORTC (BIG 2–04) SUPREMO – a phase III trial assessing the role of chest wall irradiation in ‘intermediate-risk’ breast cancer
|
Kunkler, I.
|
|
2007
|
16 |
S1 |
p. S37-
1 p.
|
artikel
|
| 105 |
P20 Multidrug resistance-related protein and P-glycoprotein expression and washout rates of 99mTc-MIBI in infiltrating ductal carcinoma of breast
|
Kwak, H.-S.
|
|
2007
|
16 |
S1 |
p. S18-
1 p.
|
artikel
|
| 106 |
P126 Neoadjuvant treatment of stage II or III breast cancer with docetaxel and low dose capecitabine, with addition of trastuzumab for HER 2 amplified tumors
|
Khan, Q.J.
|
|
2007
|
16 |
S1 |
p. S49-
1 p.
|
artikel
|
| 107 |
P124 neo-ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study [BIG 1-06/SOLTI/EGF106903]: a phase III translational study for Her2-overexpressing early breast cancer (BC)
|
Baselga, J.
|
|
2007
|
16 |
S1 |
p. S48-
1 p.
|
artikel
|
| 108 |
P80 Nipple-sparing mastectomy and immediate reconstruction: indications, technique, and results of 110 patients with breast cancer
|
Son, B.H.
|
|
2007
|
16 |
S1 |
p. S35-
1 p.
|
artikel
|
| 109 |
P46 Patterns of recurrence and prognosis in women with basal-like breast cancer
|
Dent, R.
|
|
2007
|
16 |
S1 |
p. S25-
1 p.
|
artikel
|
| 110 |
P67 Performing sentinel lymph node biopsy is associated with a significantly improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients
|
Langer, I.
|
|
2007
|
16 |
S1 |
p. S31-S32
2 p.
|
artikel
|
| 111 |
P38 Periodical mammographic screening influences stage and outcome in breast cancer patients, on a population-based observation. Results of the Italian NORA study
|
Mustacchi, G.
|
|
2007
|
16 |
S1 |
p. S23-
1 p.
|
artikel
|
| 112 |
P151 Phallus impudicus in thromboprophylaxis in breast cancer patients undergoing chemotherapy and hormonal treatment
|
Kuznecov, G.
|
|
2007
|
16 |
S1 |
p. S56-
1 p.
|
artikel
|
| 113 |
P119 Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with ErbB2-overexpressing breast cancer: Tykerb evaluation after chemotherapy (TEACH) study
|
Moy, B.
|
|
2007
|
16 |
S1 |
p. S47-
1 p.
|
artikel
|
| 114 |
P128 Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
|
Lombart-Cussac, A.
|
|
2007
|
16 |
S1 |
p. S49-S50
2 p.
|
artikel
|
| 115 |
P86 Postoperative radiotherapy (RT) after mastectomy in moderate risk early breast cancer patients
|
Mladenovic, J.
|
|
2007
|
16 |
S1 |
p. S37-
1 p.
|
artikel
|
| 116 |
P84 Post surgery adjuvant internal mammary lymph node irradiation in early breast cancer – benefit and cardiac toxicity
|
Sah, S.
|
|
2007
|
16 |
S1 |
p. S36-
1 p.
|
artikel
|
| 117 |
P8 Potentiation of erythropoietin (EPO) action by membrane steroid receptor agonists
|
Pelekanou, V.
|
|
2007
|
16 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 118 |
P94 Prediction of relapse-free period after radio- and chemo-radiotherapy in patients with breast cancer
|
Ivano, S.
|
|
2007
|
16 |
S1 |
p. S39-
1 p.
|
artikel
|
| 119 |
P51 Predictive role of immunohistochemical cytokeratine assay (IHC-CK) in neoadjuvant setting: pilot study in 19 patients treated with TAC regimen
|
Giardina, G.
|
|
2007
|
16 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 120 |
P168 Premenopausal women diagnosed with good prognosis breast cancer need not wait two years to become pregnant
|
Ives, A.
|
|
2007
|
16 |
S1 |
p. S61-
1 p.
|
artikel
|
| 121 |
P123 Preoperative sequential chemotherapy of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with stage II/IIIA breast cancer
|
Grassadonia, A.
|
|
2007
|
16 |
S1 |
p. S48-
1 p.
|
artikel
|
| 122 |
P136 Preoperative TAC (docetaxel, doxorubicin, cyclophosphamide) in conjunction with the development of a standard protocol for the management of locally advanced breast cancer
|
Chan, A.
|
|
2007
|
16 |
S1 |
p. S52-
1 p.
|
artikel
|
| 123 |
P182 Prescription pattern of aromatase inhibitors for the adjuvant therapy of breast cancer in Germany – Results of the second survey among gynaecologists and medical oncologists
|
Lüftner, D.
|
|
2007
|
16 |
S1 |
p. S65-
1 p.
|
artikel
|
| 124 |
P130 Primary progesterone therapy for operable breast cancer – review of prognostic factors and feasibility in India
|
Badwe, R.
|
|
2007
|
16 |
S1 |
p. S50-
1 p.
|
artikel
|
| 125 |
P135 Primary systemic therapy of invasive lobular cancer: Is there a role for chemotherapy?
|
Katz, A.
|
|
2007
|
16 |
S1 |
p. S51-S52
2 p.
|
artikel
|
| 126 |
P82 PRIME I: Assessing the impact of adjuvant breast radiotherapy on quality of life in low risk older patients following breast conserving surgery
|
Prescott, R.
|
|
2007
|
16 |
S1 |
p. S35-S36
2 p.
|
artikel
|
| 127 |
P61 Prognosis of breast cancer occurring in the age group below 35 years: comparison with the group above 35 years
|
Kang, S.H.
|
|
2007
|
16 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 128 |
P47 Prognosis of breast cancer patients with micrometastatic sentinel lymph nodes
|
Jinno, H.
|
|
2007
|
16 |
S1 |
p. S25-
1 p.
|
artikel
|
| 129 |
P60 Prognostic factors in breast cancer patients following neoadjuvant chemotherapy
|
Kim, J.
|
|
2007
|
16 |
S1 |
p. S29-
1 p.
|
artikel
|
| 130 |
P55 Prognostic significance of bcl-2 expression in stage III breast cancer patients who received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
|
Im, S.-A.
|
|
2007
|
16 |
S1 |
p. S28-
1 p.
|
artikel
|
| 131 |
P50 Prognostic value of apoptosis and survivin, bcl-2, p53 expression in breast cancer patients
|
Kim, S.Y.
|
|
2007
|
16 |
S1 |
p. S26-
1 p.
|
artikel
|
| 132 |
P6 Promoter methylation profiles and field defect in breast cancer
|
Lee, J.S.
|
|
2007
|
16 |
S1 |
p. S14-
1 p.
|
artikel
|
| 133 |
P171 Provider's volume and quality of breast cancer detection and treatment: a critical review
|
Hébert-Croteau, N.
|
|
2007
|
16 |
S1 |
p. S61-S62
2 p.
|
artikel
|
| 134 |
P149 Quality-of-Life comparison in post menopausal women receiving chemotherapy vs. hormone therapy in receptor positive early breast cancer: A south Indian experience
|
Bapsy, P.
|
|
2007
|
16 |
S1 |
p. S56-
1 p.
|
artikel
|
| 135 |
P59 Quantitative measurement of EGFR is a predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer
|
Rydén, L.
|
|
2007
|
16 |
S1 |
p. S29-
1 p.
|
artikel
|
| 136 |
P2 Receptor for advanced glycation end products (RAGE) – Soluble form (sRAGE) and gene polymorphisms in patients with breast cancer
|
Tesarova, P.
|
|
2007
|
16 |
S1 |
p. S13-
1 p.
|
artikel
|
| 137 |
P142 Rechallenge of patients previously treated with adjuvant anthracyclines using pegylated liposomal doxorubicin (PLD) with cyclophosphamide (C)as first-line chemotherapy for metastaticbreast cancer (MBC)
|
Trudeau, M.
|
|
2007
|
16 |
S1 |
p. S54-
1 p.
|
artikel
|
| 138 |
P138 Relationship of steroid receptor (SR) status and response to fluorouracil, doxorubicine and cyclophosphamide (FAC) primary systemic therapy (PST) in locally advanced breast cancer (LABC) patients
|
Susnjar, S.
|
|
2007
|
16 |
S1 |
p. S52-S53
2 p.
|
artikel
|
| 139 |
P37 Relevance of radial scar and breast cancer; pathologic and radiologic findings in 30 cases
|
Kil, W.H.
|
|
2007
|
16 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 140 |
P172 Relevance of the indications of adjuvant chemotherapy (AC) proposed duringthe multidisciplinary meeting (MM) for breast cancer (BC)
|
Auvray, h.
|
|
2007
|
16 |
S1 |
p. S62-
1 p.
|
artikel
|
| 141 |
P143 Retrospective pooled analysis to assess correlation between time to progression and overall survival in patients with breast cancer
|
Sherrill, B.
|
|
2007
|
16 |
S1 |
p. S54-
1 p.
|
artikel
|
| 142 |
P183 Return to work after adjuvant treatment for breast cancer
|
Osowiecka, K.
|
|
2007
|
16 |
S1 |
p. S65-
1 p.
|
artikel
|
| 143 |
P45 Risk factors of bone metastases in early breast cancer
|
Madej, B.
|
|
2007
|
16 |
S1 |
p. S25-
1 p.
|
artikel
|
| 144 |
P69 Sentinel lymph node biopsy is feasible for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy
|
Kinoshita, T.
|
|
2007
|
16 |
S1 |
p. S32-
1 p.
|
artikel
|
| 145 |
P72 Sentinel node biopsy after subareolar injection in early breast cancer
|
Armas, F.
|
|
2007
|
16 |
S1 |
p. S33-
1 p.
|
artikel
|
| 146 |
P113 Side effect profile of exemestane and anastrozole compared with tamoxifen in Japanese women: findings from N-SAS BC04 trial
|
Hozumi, Y.
|
|
2007
|
16 |
S1 |
p. S45-
1 p.
|
artikel
|
| 147 |
P41 Significant improvement in breast cancer survival through population-based mammography screening for women aged 40–49 years in Turku, Finland
|
Pylkkänen, L.
|
|
2007
|
16 |
S1 |
p. S24-
1 p.
|
artikel
|
| 148 |
P65 Sparing of completion axillary lymph node dissection in breast cancer patients with positive sentinel lymph node; usefulness of radioactivity-based sentinel lymph node status
|
Kan, S.
|
|
2007
|
16 |
S1 |
p. S31-
1 p.
|
artikel
|
| 149 |
P87 Sphere of equivalence for tumour-bed recurrence after intraoperative radiotherapy with low-energy X-rays compared with external beam radiotherapy
|
Herskin, C.
|
|
2007
|
16 |
S1 |
p. S37-
1 p.
|
artikel
|
| 150 |
P21 Subclassification of BIRAD category 4 microcalcification according to morphologic difference – more accurate method to detect DCIS or breast cancer
|
Jeong, J.
|
|
2007
|
16 |
S1 |
p. S18-
1 p.
|
artikel
|
| 151 |
P146 Survival after first recurrence of breast cancer
|
Kang, S.H.
|
|
2007
|
16 |
S1 |
p. S55-
1 p.
|
artikel
|
| 152 |
P157 Survival in breast cancer patients with bone metastases
|
El-Habbash, M.
|
|
2007
|
16 |
S1 |
p. S58-
1 p.
|
artikel
|
| 153 |
P156 Survival of breast cancer patients treated in Tripoli/Libya 2000–2005
|
El-Habbash, M.
|
|
2007
|
16 |
S1 |
p. S58-
1 p.
|
artikel
|
| 154 |
P77 Synchronous bilateral breast cancer: comparison of modified radical mastectomy performed with ultrasound scalpel and electrocautery
|
Matkowski, R.
|
|
2007
|
16 |
S1 |
p. S34-
1 p.
|
artikel
|
| 155 |
P5 Targeting heparan sulfation in breast cancer therapeutics
|
Yi, G.
|
|
2007
|
16 |
S1 |
p. S14-
1 p.
|
artikel
|
| 156 |
P1 The animal model for development of primary hormone therapy of breast cancer
|
Burlaka, D.
|
|
2007
|
16 |
S1 |
p. S13-
1 p.
|
artikel
|
| 157 |
P52 The axillary lymph node status (ALNS) of breast cancers by combined ER, PR and HER-2 expression: Triple positive tumours are more likely lymph node positive
|
Van Calster, B.
|
|
2007
|
16 |
S1 |
p. S27-
1 p.
|
artikel
|
| 158 |
P7 The CHEK2 1100delC mutation is not present in Korean patients with breast cancer tested for BRCA1 and BRCA2 mutation
|
Choi, D.H.
|
|
2007
|
16 |
S1 |
p. S14-
1 p.
|
artikel
|
| 159 |
P16 The effect of a cyclooxygenase-2 inhibitor on proliferating activity in breast carcinoma: first results
|
Buxant, F.
|
|
2007
|
16 |
S1 |
p. S17-
1 p.
|
artikel
|
| 160 |
P165 The effect of ethnicity and life style factors on breast cancer presentation and prognosis
|
Shklar, Z.
|
|
2007
|
16 |
S1 |
p. S60-
1 p.
|
artikel
|
| 161 |
P74 The effect of ipsilateral breast tumor recurrence on survival after breast conserving surgery in breast cancer
|
Shin, M.J.
|
|
2007
|
16 |
S1 |
p. S33-
1 p.
|
artikel
|
| 162 |
P114 The effects of toremifene (TOR) and anastrozole (ANA) on serum lipids and bone metabolism in postmenopausal patients with estrogen receptor (ER) positive breast cancer; multi-center study
|
Mitsuyama, S.
|
|
2007
|
16 |
S1 |
p. S45-
1 p.
|
artikel
|
| 163 |
P134 The experience of sentinel lymph node biopsy in Chinese breast cancer patients with prior neo-adjuvant chemotherapy
|
Kwong, A.
|
|
2007
|
16 |
S1 |
p. S51-
1 p.
|
artikel
|
| 164 |
P131 The neoadjuvant endocrinetherapy vs chemotherapy in postmenopausal woment with ER-positive breast cancer
|
Semiglazov, V.F.
|
|
2007
|
16 |
S1 |
p. S50-
1 p.
|
artikel
|
| 165 |
P170 The number needed to treat (NNT) as a measure of drug efficacy: the case of aromatase inhibitors (AIs) in post menopausal women with early breast cancer
|
Rugo, H.
|
|
2007
|
16 |
S1 |
p. S61-
1 p.
|
artikel
|
| 166 |
P167 The opinion of breast cancer patients about disease, therapy and follow-up
|
Tschurtschenthale, G.
|
|
2007
|
16 |
S1 |
p. S60-
1 p.
|
artikel
|
| 167 |
P163 The prognosis of small breast cancers
|
Sundquist, M.
|
|
2007
|
16 |
S1 |
p. S59-S60
2 p.
|
artikel
|
| 168 |
P75 Therapeutic results of breast conserving surgery combined with radiotherapy
|
Iwamot, M.
|
|
2007
|
16 |
S1 |
p. S33-S34
2 p.
|
artikel
|
| 169 |
P58 The role of Epidermal Growth Factor Receptor, (EGFR) and Cyclooxygenase-2 (COX-2) expression in predicting lymph node metastasis in infiltrating ductal carcinoma of the breast
|
Darmawan Machsoos, B.
|
|
2007
|
16 |
S1 |
p. S29-
1 p.
|
artikel
|
| 170 |
P148 The unique psychosocial issues for women diagnosed with gestational breast cancer
|
Ives, A.
|
|
2007
|
16 |
S1 |
p. S55-
1 p.
|
artikel
|
| 171 |
P43 The validity of complex breast cysts after surgery
|
Tea, M.K.
|
|
2007
|
16 |
S1 |
p. S24-
1 p.
|
artikel
|
| 172 |
P162 Time distribution of mortality risk for breast cancer and its clinical application
|
Yin, W.J.
|
|
2007
|
16 |
S1 |
p. S59-
1 p.
|
artikel
|
| 173 |
P30 Tissue microarray-based studies of patients with lymph node-negative breast carcinoma show that HER-2/neu overexpression is an important predictive marker of poor prognosis
|
Ahn, J.H.
|
|
2007
|
16 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 174 |
P103 Toxicity and tolerability of the anthracycline-containing regimen in adjuvant chemotherapy for breast cancer
|
Jagiello-Gruszfeld, A.
|
|
2007
|
16 |
S1 |
p. S42-
1 p.
|
artikel
|
| 175 |
P54 Triple positive (ER+/PR+/HER-2+) breast carcinomas occur at a younger age than all other ER/PR/HER-2 breast cancer phenotypes
|
Neven, P.
|
|
2007
|
16 |
S1 |
p. S27-S28
2 p.
|
artikel
|
| 176 |
P145 TTFields–anovel electric field based treatment modality for pre-surgical treatment of breast cancer
|
Morant, R.
|
|
2007
|
16 |
S1 |
p. S55-
1 p.
|
artikel
|
| 177 |
P161 Tumor characteristics and clinical outcome of elderly women with breast cancer in Korea
|
Lee, J.S.
|
|
2007
|
16 |
S1 |
p. S59-
1 p.
|
artikel
|
| 178 |
P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)
|
Brufsky, A.
|
|
2007
|
16 |
S1 |
p. S57-
1 p.
|
artikel
|
| 179 |
P19 Urinary estrogen metabolites and risk of breast cancer and epithelian ovarian cancer
|
Antonova, I.
|
|
2007
|
16 |
S1 |
p. S17-
1 p.
|
artikel
|
| 180 |
P23 What kind of calcified lesion can be diagnosed as ductal carcinoma in situ (DCIS) exactly by needle biopsy?
|
Asag, S.
|
|
2007
|
16 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 181 |
P24 X-ray microscopic imaging of female breast tissues by synchrotron radiation
|
Park, S.
|
|
2007
|
16 |
S1 |
p. S19-
1 p.
|
artikel
|
| 182 |
P78 Y-shaped incision for modified radical mastectomy with level III axillary dissection in obese woman
|
Szynglarewicz, B.
|
|
2007
|
16 |
S1 |
p. S34-
1 p.
|
artikel
|
| 183 |
S40 Adjuvant therapies and thrombosis: How to avoid the problem?
|
Levine, M.N.
|
|
2007
|
16 |
S1 |
p. S11-
1 p.
|
artikel
|
| 184 |
S36 Adjuvant treatment of elderly breast cancer patients
|
Muss, H.
|
|
2007
|
16 |
S1 |
p. S10-
1 p.
|
artikel
|
| 185 |
S35 Adjuvant treatment of the very young woman
|
Pritchard, K.
|
|
2007
|
16 |
S1 |
p. S10-
1 p.
|
artikel
|
| 186 |
S11 Angiogenesis as targeted breast cancer therapy
|
Hayes, D.F.
|
|
2007
|
16 |
S1 |
p. S3-
1 p.
|
artikel
|
| 187 |
S27 Application of aromatase inhibitors in endocrine responsive breast cancers
|
Goss, P.E.
|
|
2007
|
16 |
S1 |
p. S8-
1 p.
|
artikel
|
| 188 |
S33 Benefit with adjuvant taxanes and endocrine responsiveness in breast cancer (BC)
|
Martin, M.
|
|
2007
|
16 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 189 |
S9 Blocking crosstalk between ER and growth factor receptors to circumvent endocrine resistance
|
Osborne, K.
|
|
2007
|
16 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 190 |
S38 Breast cancer and pregnancy
|
Ring, A.E.
|
|
2007
|
16 |
S1 |
p. S11-
1 p.
|
artikel
|
| 191 |
S6 Breast cancer genetics: clues to tumor biology
|
Garber, J.
|
|
2007
|
16 |
S1 |
p. S2-
1 p.
|
artikel
|
| 192 |
S21 Breast surgery in advanced breast cancer: The issue of local control in the presence of metastases
|
Wood, W.C.
|
|
2007
|
16 |
S1 |
p. S6-
1 p.
|
artikel
|
| 193 |
S30 Chemotherapy for endocrine responsive disease: An evolving story
|
Albain, K.
|
|
2007
|
16 |
S1 |
p. S9-
1 p.
|
artikel
|
| 194 |
S39 Cognitive side-effects of adjuvant treatments
|
Burstein, H.J.
|
|
2007
|
16 |
S1 |
p. S11-
1 p.
|
artikel
|
| 195 |
S34 Combining adjuvant chemotherapy and biologicals
|
Perez, E.
|
|
2007
|
16 |
S1 |
p. S10-
1 p.
|
artikel
|
| 196 |
S19 Controversies in the use of sentinel nodes in the elderly
|
Forbes, J.F.
|
|
2007
|
16 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 197 |
S20 Controversies in the use of sentinel nodes: Microinvasion, post-surgery and after preoperative systemic treatment
|
Verones, P.
|
|
2007
|
16 |
S1 |
p. S6-
1 p.
|
artikel
|
| 198 |
S18 DCIS as a major dilemma
|
Morrow, M.
|
|
2007
|
16 |
S1 |
p. S5-
1 p.
|
artikel
|
| 199 |
S16 Disseminated tumor cells: Are they ready for clinical use?
|
Braun, S.
|
|
2007
|
16 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 200 |
S41 Fertility and adjuvant treatment in young women with breast cancer
|
Partridge, A.H.
|
|
2007
|
16 |
S1 |
p. S11-S12
2 p.
|
artikel
|
| 201 |
S37 How to treat male breast cancer
|
Bergqvist, J.
|
|
2007
|
16 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 202 |
S12 Immunity and breast cancer cells: Role of vaccination
|
Curigliano, G.
|
|
2007
|
16 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 203 |
S10 Inflammation and breast cancer: Hypothesis for targeted therapies
|
Mantovani, A.
|
|
2007
|
16 |
S1 |
p. S3-
1 p.
|
artikel
|
| 204 |
S14 Local staging of breast cancer with mammography, ultrasound, and MRI: One step forward –two steps back?
|
Kuhl, C.
|
|
2007
|
16 |
S1 |
p. S4-
1 p.
|
artikel
|
| 205 |
S13 Metastatic genes and tumor geometry
|
Norton, L.
|
|
2007
|
16 |
S1 |
p. S4-
1 p.
|
artikel
|
| 206 |
S29 Optimizing treatment and prevention of breast cancer: Time for a change?
|
Jordan, V.C.
|
|
2007
|
16 |
S1 |
p. S9-
1 p.
|
artikel
|
| 207 |
S28 Ovarian function suppression in the adjuvant program
|
Davidson, N.E.
|
|
2007
|
16 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 208 |
S23 Partial breast irradiation: Ready for Routine?
|
Orecchia, R.
|
|
2007
|
16 |
S1 |
p. S7-
1 p.
|
artikel
|
| 209 |
S17 Pathological definitions of invasion, metastatic potential and responsiveness to targeted therapies
|
Viale, G.
|
|
2007
|
16 |
S1 |
p. S5-
1 p.
|
artikel
|
| 210 |
S15 Role of baseline staging and follow-up: between reassurance and economic constraints
|
Winer, E.
|
|
2007
|
16 |
S1 |
p. S4-
1 p.
|
artikel
|
| 211 |
S42 Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients – design and baseline data ‘LIBERATE’ trial
|
Kubista, E.
|
|
2007
|
16 |
S1 |
p. S12-
1 p.
|
artikel
|
| 212 |
S22 State of the art of post mastectomy radiation therapy (PMRT)
|
Harris, J.R.
|
|
2007
|
16 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 213 |
S24 Systemic adjuvant therapies and radiotherapy to the conserved breast: Strategies revisited
|
Bartelink, H.
|
|
2007
|
16 |
S1 |
p. S7-
1 p.
|
artikel
|
| 214 |
S32 Taxing the taxanes in adjuvant therapy
|
Hudis, C.
|
|
2007
|
16 |
S1 |
p. S9-
1 p.
|
artikel
|
| 215 |
S25 The diversity of small tumors around the world: Are there implications for local and systemic therapies?
|
Kurebayash, J.
|
|
2007
|
16 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 216 |
S4 The evolution of adjuvant therapies – and the heart?
|
Suter, T.
|
|
2007
|
16 |
S1 |
p. S1-
1 p.
|
artikel
|
| 217 |
S2 The evolution of endocrine therapies
|
Smith, I.
|
|
2007
|
16 |
S1 |
p. S1-
1 p.
|
artikel
|
| 218 |
S5 The evolution of pathology in breast cancer: Relations between cellular origin and functional classification
|
Palacios, J.
|
|
2007
|
16 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 219 |
S1 The evolution of targeted biological therapies
|
Sledge, G.
|
|
2007
|
16 |
S1 |
p. S1-
1 p.
|
artikel
|
| 220 |
S3 The evolution of treatment strategies: Aiming at the target
|
Piccart-Gebhart, M.J.
|
|
2007
|
16 |
S1 |
p. S1-
1 p.
|
artikel
|
| 221 |
S7 Therapeutic implications of the breast tumor intrinsic subtypes
|
Perou, C.M.
|
|
2007
|
16 |
S1 |
p. S2-
1 p.
|
artikel
|
| 222 |
S8 The story of steroid hormone receptors: polymorphisms and endocrine responsiveness
|
Ciana, P.
|
|
2007
|
16 |
S1 |
p. S2-
1 p.
|
artikel
|
| 223 |
S26 Using clinical trial data to tailor adjuvant treatments for individual patients
|
Gelber, R.D.
|
|
2007
|
16 |
S1 |
p. S8-
1 p.
|
artikel
|
| 224 |
S31 Using specific cytotoxics with a targeted mind
|
Di Leo, A.
|
|
2007
|
16 |
S1 |
p. S9-
1 p.
|
artikel
|
Tijdschrift beschrijving